Merck Specialities collaborates with hospitals on oral cancer protection

IMT News Desk
IMT News Desk
· 2 min read

Individuals are being encouraged to perform a quick self-check using mirrors

Merck Specialities, in collaboration with leading hospitals across India, has launched the Two-Minute Action Oral Cancer Protection campaign with the hashtag #ActAgainstOralCancer.

The nationwide effort aims to tackle the alarming rise in oral cancer cases by encouraging individuals to perform a quick self-check using mirrors that are almost always available to one and all.

Through this initiative, patients who are visiting hospitals can also activate this self-check-up, where mirrors will be strategically placed in the hospital waiting areas. Dr Jeyhan Dhabhar, Consultant Medical Oncologist, Dr Jimmy Mirani, Consultant Medical Oncologist, Dr Delnaz J. Dhabhar, MD, Physician and Palliative Care Expert, and medical staff were present. 

“The campaign underscores the importance of a quick monthly self-check that is just two minutes in front of a mirror can make all the difference. Early-stage diagnosis means faster, more effective treatment and a much better chance of recovery,” said Dr Jeyhan Dhabhar, Consultant Medical Oncologist, BND Onco Centre at K G Mittal Hospital. 

“This campaign encourages individuals to follow the simple two-minute self-check every month, as early detection is the best prevention. LOOK at the entire mouth in the mirror for white or red patches in the mouth, ulcers that don’t heal within two weeks, and unusual bleeding or loose teeth. FEEL for changes, like lumps or swelling in the jaw or neck, hoarseness or voice change, persistent pain in the ear, or when swallowing. ACT with urgency if you notice signs, and don’t delay. Visit the doctor to rule them out as early detection equals better chances of cure,” underscored Dr Jimmy Mirani, Consultant Medical Oncologist, BND Onco Centre.

Palliative care for oral cancer includes pain management, nutritional support, emotional counselling, and assistance with speech and swallowing to improve the patient’s quality of life. Early palliative care not only alleviates pain but also enhances the overall quality of life for patients, aiding in informed decision-making throughout the disease trajectory. There should be awareness and accessibility of palliative services to ensure holistic support for patients and their families,” concluded Dr Delnaz J Dhabhar, MD, Physician and Palliative Care Expert, BND Onco Centre.

Read Next

India successfully validates the first indigenous HPV test for Cervical Cancer screening
News
June 13, 2026

India successfully validates the first indigenous HPV test for Cervical Cancer screening

India has achieved a significant milestone in cervical cancer prevention with the successful validation of the country’s first indigenous HPV DNA tests, which meet international standards for cervical cancer screening. Published in the International Journal of Cancer, a multicentre study involving leading Indian and international institutions found that Molbio Diagnostics Truenat HPV-HR Plus met the […]
Article by: IMT News Desk
Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk